Navigation Links
MHRA Issues Notice of Acceptance for Phase 3 Trial of GALNS for the Treatment of MPS IVA
Date:12/14/2010

world for a total of 2,500 to 3,000 patients. Over 1,000 MPS IVA patients worldwide have been identified through The International Morquio Organization (IMO) survey and the BioMarin MorCAP registry program.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Other product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in clinical development for the treatment of MPS IVA, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking StatementThis press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the development of its program for MPS IVA, and particularly the timing and conduct of clinical trials related thereto, and expectations regarding filings with regulatory agencies. These forward-looking statements ar
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
2. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
3. European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
4. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
5. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
6. QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Womens Health Issues
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
8. Lupus Under the Spotlight: U.S. Congress Shows Support for Womens Health Issues
9. European Unions CHMP Issues Positive Opinion on Sugammadex
10. Newly Published Study Shows OPKOs siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
11. Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ) ... Diagnostic Testing Market - Forecasts to 2019: Expected ... and is expected to be valued at USD ... http://photos.prnewswire.com/prnh/20130307/600769 ... segmented according to immunoprotein types which include immunoglobulins, ...
(Date:7/11/2014)... July 11, 2014 ... Safety & Health Expo 2014 were a ... to London , plus ... exhibition.          (Logo: ... )      (Photo: ...
(Date:7/10/2014)... July 11, 2014  Major advances in radiation ... are being highlighted in a three-day Oncology Summit ... from 10-12 July, 2014.  Renowned national and international cancer experts ... practices and exchange knowledge on modern technologies making ... efficient. The Summit will address ...
Breaking Medicine Technology:Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
... Aug. 17, 2011 Reportlinker.com announces that ... in its catalogue: Levosimendan ... http://www.reportlinker.com/p0483048/Levosimendan---Comprehensive-patent-search.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology Eliminate unnecessary ... patent information. Pipeline Developer is ...
... 16, 2011 Savient Pharmaceuticals, Inc. (NASDAQ: ... KRYSTEXXA® (pegloticase) Phase III clinical studies in patients with ... The Journal of the American Medical Association ( ... resulted in significant and sustained reductions in uric acid ...
Cached Medicine Technology:Levosimendan - Comprehensive Patent Search 2Levosimendan - Comprehensive Patent Search 3Levosimendan - Comprehensive Patent Search 4Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 2Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 3Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 4Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 5Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 6Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 7Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 8
(Date:7/11/2014)... City, UT (PRWEB) July 11, 2014 WWTrek ... work at the Kilimanjaro Kids Community in Tanzania. Opened in ... goats, 150 chickens, and two cows. HOP Founder, Dean Cardinale, ... education for some of the orphaned children he encountered while ... HOP Team visited the children, who have all made astounding ...
(Date:7/11/2014)... Francisco shows that an "expressive therapy" group intervention ... with HIV disclose their health status and improves ... quality of their relationships., "Medication alone is totally ... Machtinger, MD, director of the Women,s HIV Program ... are on effective antiretroviral therapy but far too ...
(Date:7/11/2014)... July 11, 2014 Recently, iFitDress.com, a ... occasion outfits, has released its new collection of ... the company has announced that all these beautiful items ... The deadline of the special offer is July 22. ... major officials pay close attention to customer satisfaction. On ...
(Date:7/11/2014)... July 11, 2014 Organic Crop ... being launched into the limelight over the past decade. ... was once considered to be an alternative food eaten ... are now purchasing organic food.” Organic crop farmers have ... vegetables, grains, nuts and herbs over the past five ...
(Date:7/11/2014)... personalized medicine may be just around the corner, thanks ... Yu and scientists at Massachusetts General Hospital and Harvard ... Science , Yu and her colleagues report how ... streams of six patients. Some of these deadly cancer ... and establish secondary tumors in vital organs such as ...
Breaking Medicine News(10 mins):Health News:Human Outreach Project Sees Incredible Progress in the Kilimanjaro Kids Community 2Health News:'Expressive therapy" intervention assists women living with HIV 2Health News:Worldwide Chic Ladies Can Buy Cheap Evening Dresses at iFitDress.com 2Health News:Organic Crop Farming in Australia Industry Market Research Report Now Available from IBISWorld 2Health News:Organic Crop Farming in Australia Industry Market Research Report Now Available from IBISWorld 3Health News:Organic Crop Farming in Australia Industry Market Research Report Now Available from IBISWorld 4
... Beneficial bacteria found in healthy women help to reduce the ... more difficult for the virus to spread, boosting the possibility ... against HIV. , The findings come from physicians and scientists ... Medical Center, who worked together in an effort to learn ...
... a national healthcare,management and technology company, has renewed ... West Virginia to provide Revenue Cycle,Management (RCM), ASP ... physician groups., St. Mary,s Medical Center provides ... in several specialties. MED3OOO,s subsidiary,MED3OOO Health Solutions of ...
... CYT, MONTREAL, Feb. 7 /PRNewswire-FirstCall/ - CryoCath (TSX: CYT), will,hold a ... (Eastern Time) on Thursday, February 14, 2008. The Company,will report its results ... 14., DATE: ... ...
... Gentiva Health,Services, Inc. (Nasdaq: GTIV ), ... announced today that its CareCentrix(R),ancillary care benefit management ... homecare contract with CIGNA HealthCare, which will,provide for ... CIGNA,members through January 31, 2011. The extension amends ...
... employee benefit Increasing animal obesity, more and better pet care ... ... The insurance industry is,going to the dogs ... and cats., Officials ... friends and the growth trends for pet insurance are,only going to accelerate ...
... close ties with parents is obviously good for preschoolers, ... the preschoolers are better able to control their own ... , Thats the finding of a new study conducted ... in the January/February 2008 issue of the journal Child ...
Cached Medicine News:Health News:'Good bacteria' in women give clues for slowing HIV transmission 2Health News:'Good bacteria' in women give clues for slowing HIV transmission 3Health News:St. Mary's Medical Center Renews RCM & Technology With MED3000 2Health News:CryoCath to Hold First Quarter 2008 Conference Call and Webcast 2Health News:Gentiva(R) Health Services and CIGNA HealthCare Extend National Homecare Contract Through January 31, 2011 2Health News:Gentiva(R) Health Services and CIGNA HealthCare Extend National Homecare Contract Through January 31, 2011 3Health News:PetFirst: Pet Insurance To Be More Popular in 2008 2Health News:Close ties between parents and babies yield benefits for preschoolers 2
... peripheral nerve stimulator from B. Braun Medical. ... nerve stimulator functionality for over 10 years. ... available, a unique, under-the-glove hand held remote ... Dig. It allows the anesthesia provider operating ...
... Control allows hands-free operation in nerve locator ... 5.0 mA) with SoloStim provides a wide ... control when close to nerve., ,Supported ... block products, including the clinically proven ProBloc™ ...
... your investment., ,The Centiva/5 Critical Care Ventilator ... demands of the critical care environment. The Centiva ... combining a compact size with high levels of ... space around the patients bed and allows you ...
... Mesh Elastic is a lightweight and large pore ... mesh is able to adapt to all movements ... honeycomb like structure with the large pores enables ... The mesh is ideal for incisional hernia repair ...
Medicine Products: